Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Proximity to overhead power lines and childhood leukaemia: an international pooled analysis.

Amoon AT, Crespi CM, Ahlbom A, Bhatnagar M, Bray I, Bunch KJ, Clavel J, Feychting M, Hémon D, Johansen C, Kreis C, Malagoli C, Marquant F, Pedersen C, Raaschou-Nielsen O, Röösli M, Spycher BD, Sudan M, Swanson J, Tittarelli A, Tuck DM, Tynes T, Vergara X, Vinceti M, Wünsch-Filho V, Kheifets L.

Br J Cancer. 2018 Aug;119(3):364-373. doi: 10.1038/s41416-018-0097-7. Epub 2018 May 29.

2.

CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial.

Oki Y, Kelly KR, Flinn I, Patel MR, Gharavi R, Ma A, Parker J, Hafeez A, Tuck D, Younes A.

Haematologica. 2017 Nov;102(11):1923-1930. doi: 10.3324/haematol.2017.172882. Epub 2017 Aug 31.

3.

New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016.

Adusumilli PS, Cha E, Cornfeld M, Davis T, Diab A, Dubensky TW Jr, Evans E, Grogan JL, Irving BA, Leidner RS, Olwill SA, Soon-Shiong P, Triebel F, Tuck D, Bot A, Dansey RD, Drake CG, Freeman GJ, Ibrahim R, Patel S, Chen DS.

J Immunother Cancer. 2017 Jun 20;5:50. doi: 10.1186/s40425-017-0253-2. eCollection 2017. Review.

4.

Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.

Sun K, Atoyan R, Borek MA, Dellarocca S, Samson ME, Ma AW, Xu GX, Patterson T, Tuck DP, Viner JL, Fattaey A, Wang J.

Mol Cancer Ther. 2017 Feb;16(2):285-299. doi: 10.1158/1535-7163.MCT-16-0390. Epub 2016 Dec 15.

5.

Estrogen Drives Cellular Transformation and Mutagenesis in Cells Expressing the Breast Cancer-Associated R438W DNA Polymerase Lambda Protein.

Nemec AA, Bush KB, Towle-Weicksel JB, Taylor BF, Schulz V, Weidhaas JB, Tuck DP, Sweasy JB.

Mol Cancer Res. 2016 Nov;14(11):1068-1077. Epub 2016 Sep 12.

6.

Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.

Goel S, Wang Q, Watt AC, Tolaney SM, Dillon DA, Li W, Ramm S, Palmer AC, Yuzugullu H, Varadan V, Tuck D, Harris LN, Wong KK, Liu XS, Sicinski P, Winer EP, Krop IE, Zhao JJ.

Cancer Cell. 2016 Mar 14;29(3):255-269. doi: 10.1016/j.ccell.2016.02.006.

7.

Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer.

Varadan V, Gilmore H, Miskimen KL, Tuck D, Parsai S, Awadallah A, Krop IE, Winer EP, Bossuyt V, Somlo G, Abu-Khalaf MM, Fenton MA, Sikov W, Harris LN.

Clin Cancer Res. 2016 Jul 1;22(13):3249-59. doi: 10.1158/1078-0432.CCR-15-2021. Epub 2016 Feb 3.

8.

Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors.

Abu-Khalaf MM, Baumgart MA, Gettinger SN, Doddamane I, Tuck DP, Hou S, Chen N, Sullivan C, Lezon-Geyda K, Zelterman D, Hatzis C, Deshpande H, Digiovanna MP, Azodi M, Schwartz PE, Harris LN.

Cancer. 2015 Jun 1;121(11):1817-26. doi: 10.1002/cncr.29254. Epub 2015 Feb 3.

9.

Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy.

Shahabi V, Postow MA, Tuck D, Wolchok JD.

Am J Clin Oncol. 2015 Feb;38(1):90-7. doi: 10.1097/COC.0b013e3182868ec8. Review.

PMID:
25616204
10.

Extended lifespan and reduced adiposity in mice lacking the FAT10 gene.

Canaan A, DeFuria J, Perelman E, Schultz V, Seay M, Tuck D, Flavell RA, Snyder MP, Obin MS, Weissman SM.

Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5313-8. doi: 10.1073/pnas.1323426111. Epub 2014 Mar 24.

11.

Molecular phenotypes in triple negative breast cancer from African American patients suggest targets for therapy.

Lindner R, Sullivan C, Offor O, Lezon-Geyda K, Halligan K, Fischbach N, Shah M, Bossuyt V, Schulz V, Tuck DP, Harris LN.

PLoS One. 2013 Nov 18;8(11):e71915. doi: 10.1371/journal.pone.0071915. eCollection 2013.

12.

Translating next generation sequencing to practice: opportunities and necessary steps.

Kamalakaran S, Varadan V, Janevski A, Banerjee N, Tuck D, McCombie WR, Dimitrova N, Harris LN.

Mol Oncol. 2013 Aug;7(4):743-55. doi: 10.1016/j.molonc.2013.04.008. Epub 2013 May 15. Review.

13.

HDAC inhibitors induce transcriptional repression of high copy number genes in breast cancer through elongation blockade.

Kim YJ, Greer CB, Cecchini KR, Harris LN, Tuck DP, Kim TH.

Oncogene. 2013 Jun 6;32(23):2828-35. doi: 10.1038/onc.2013.32. Epub 2013 Feb 25.

14.

PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer.

Martín M, Prat A, Rodríguez-Lescure A, Caballero R, Ebbert MT, Munárriz B, Ruiz-Borrego M, Bastien RR, Crespo C, Davis C, Rodríguez CA, López-Vega JM, Furió V, García AM, Casas M, Ellis MJ, Berry DA, Pitcher BN, Harris L, Ruiz A, Winer E, Hudis C, Stijleman IJ, Tuck DP, Carrasco E, Perou CM, Bernard PS.

Breast Cancer Res Treat. 2013 Apr;138(2):457-66. doi: 10.1007/s10549-013-2416-2. Epub 2013 Feb 20.

15.

Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer.

Neumeister VM, Sullivan CA, Lindner R, Lezon-Geyda K, Li J, Zavada J, Martel M, Glazer PM, Tuck DP, Rimm DL, Harris L.

Breast Cancer Res Treat. 2012 Nov;136(1):67-75. doi: 10.1007/s10549-012-2232-0. Epub 2012 Sep 14.

PMID:
22976806
16.

DNA polymerase β variant Ile260Met generates global gene expression changes related to cellular transformation.

Donigan KA, Tuck D, Schulz V, Sweasy JB.

Mutagenesis. 2012 Nov;27(6):683-91. doi: 10.1093/mutage/ges034. Epub 2012 Aug 21.

17.

Tcf7 is an important regulator of the switch of self-renewal and differentiation in a multipotential hematopoietic cell line.

Wu JQ, Seay M, Schulz VP, Hariharan M, Tuck D, Lian J, Du J, Shi M, Ye Z, Gerstein M, Snyder MP, Weissman S.

PLoS Genet. 2012;8(3):e1002565. doi: 10.1371/journal.pgen.1002565. Epub 2012 Mar 8.

18.

Favorable outcome associated with an IGF-1 ligand signature in breast cancer.

Mu L, Tuck D, Katsaros D, Lu L, Schulz V, Perincheri S, Menato G, Scarampi L, Harris L, Yu H.

Breast Cancer Res Treat. 2012 May;133(1):321-31. doi: 10.1007/s10549-012-1952-5.

PMID:
22297468
19.

Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1.

Lin W, Cao J, Liu J, Beshiri ML, Fujiwara Y, Francis J, Cherniack AD, Geisen C, Blair LP, Zou MR, Shen X, Kawamori D, Liu Z, Grisanzio C, Watanabe H, Minamishima YA, Zhang Q, Kulkarni RN, Signoretti S, Rodig SJ, Bronson RT, Orkin SH, Tuck DP, Benevolenskaya EV, Meyerson M, Kaelin WG Jr, Yan Q.

Proc Natl Acad Sci U S A. 2011 Aug 16;108(33):13379-86. doi: 10.1073/pnas.1110104108. Epub 2011 Jul 25.

20.

NFBD1/MDC1 regulates Cav1 and Cav2 independently of DNA damage and p53.

Wilson KA, Colavito SA, Schulz V, Wakefield PH, Sessa W, Tuck D, Stern DF.

Mol Cancer Res. 2011 Jun;9(6):766-81. doi: 10.1158/1541-7786.MCR-10-0317. Epub 2011 May 6.

21.

MicroRNA signatures differentiate melanoma subtypes.

Chan E, Patel R, Nallur S, Ratner E, Bacchiocchi A, Hoyt K, Szpakowski S, Godshalk S, Ariyan S, Sznol M, Halaban R, Krauthammer M, Tuck D, Slack FJ, Weidhaas JB.

Cell Cycle. 2011 Jun 1;10(11):1845-52. Epub 2011 Jun 1.

22.

A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis.

Paranjape T, Heneghan H, Lindner R, Keane FK, Hoffman A, Hollestelle A, Dorairaj J, Geyda K, Pelletier C, Nallur S, Martens JW, Hooning MJ, Kerin M, Zelterman D, Zhu Y, Tuck D, Harris L, Miller N, Slack F, Weidhaas J.

Lancet Oncol. 2011 Apr;12(4):377-86. doi: 10.1016/S1470-2045(11)70044-4. Epub 2011 Mar 22. Erratum in: Lancet Oncol. 2011 Jun;12(6):522.

23.

Valproic acid antagonizes the capacity of other histone deacetylase inhibitors to activate the Epstein-barr virus lytic cycle.

Daigle D, Gradoville L, Tuck D, Schulz V, Wang'ondu R, Ye J, Gorres K, Miller G.

J Virol. 2011 Jun;85(11):5628-43. doi: 10.1128/JVI.02659-10. Epub 2011 Mar 16.

24.

GPHMM: an integrated hidden Markov model for identification of copy number alteration and loss of heterozygosity in complex tumor samples using whole genome SNP arrays.

Li A, Liu Z, Lezon-Geyda K, Sarkar S, Lannin D, Schulz V, Krop I, Winer E, Harris L, Tuck D.

Nucleic Acids Res. 2011 Jul;39(12):4928-41. doi: 10.1093/nar/gkr014. Epub 2011 Mar 11.

25.

Single-lineage transcriptome analysis reveals key regulatory pathways in primitive erythroid progenitors in the mouse embryo.

Isern J, He Z, Fraser ST, Nowotschin S, Ferrer-Vaquer A, Moore R, Hadjantonakis AK, Schulz V, Tuck D, Gallagher PG, Baron MH.

Blood. 2011 May 5;117(18):4924-34. doi: 10.1182/blood-2010-10-313676. Epub 2011 Jan 24.

26.

Germline competency of parthenogenetic embryonic stem cells from immature oocytes of adult mouse ovary.

Liu Z, Hu Z, Pan X, Li M, Togun TA, Tuck D, Pelizzola M, Huang J, Ye X, Yin Y, Liu M, Li C, Chen Z, Wang F, Zhou L, Chen L, Keefe DL, Liu L.

Hum Mol Genet. 2011 Apr 1;20(7):1339-52. doi: 10.1093/hmg/ddr016. Epub 2011 Jan 14.

27.

Modeling the clonal heterogeneity of stem cells.

Tuck DP, Miranker W.

Theor Biol Med Model. 2010 Nov 17;7:44. doi: 10.1186/1742-4682-7-44.

28.

MicroRNA signatures differentiate uterine cancer tumor subtypes.

Ratner ES, Tuck D, Richter C, Nallur S, Patel RM, Schultz V, Hui P, Schwartz PE, Rutherford TJ, Weidhaas JB.

Gynecol Oncol. 2010 Sep;118(3):251-7. doi: 10.1016/j.ygyno.2010.05.010. Epub 2010 Jun 9.

29.

MixHMM: inferring copy number variation and allelic imbalance using SNP arrays and tumor samples mixed with stromal cells.

Liu Z, Li A, Schulz V, Chen M, Tuck D.

PLoS One. 2010 Jun 1;5(6):e10909. doi: 10.1371/journal.pone.0010909.

30.

Downstream targets of HOXB4 in a cell line model of primitive hematopoietic progenitor cells.

Lee HM, Zhang H, Schulz V, Tuck DP, Forget BG.

Blood. 2010 Aug 5;116(5):720-30. doi: 10.1182/blood-2009-11-253872. Epub 2010 Apr 19.

31.

Upregulation of STAT3 marks Burkitt lymphoma cells refractory to Epstein-Barr virus lytic cycle induction by HDAC inhibitors.

Daigle D, Megyola C, El-Guindy A, Gradoville L, Tuck D, Miller G, Bhaduri-McIntosh S.

J Virol. 2010 Jan;84(2):993-1004. doi: 10.1128/JVI.01745-09. Epub 2009 Nov 4.

32.
33.

Distinct human papillomavirus type 16 methylomes in cervical cells at different stages of premalignancy.

Brandsma JL, Sun Y, Lizardi PM, Tuck DP, Zelterman D, Haines GK 3rd, Martel M, Harigopal M, Schofield K, Neapolitano M.

Virology. 2009 Jun 20;389(1-2):100-7. doi: 10.1016/j.virol.2009.03.029. Epub 2009 May 13.

34.

Global variation in CYP2C8-CYP2C9 functional haplotypes.

Speed WC, Kang SP, Tuck DP, Harris LN, Kidd KK.

Pharmacogenomics J. 2009 Aug;9(4):283-90. doi: 10.1038/tpj.2009.10. Epub 2009 Apr 21.

35.

Quantitative assessment of tissue biomarkers and construction of a model to predict outcome in breast cancer using multiple imputation.

Emerson JW, Dolled-Filhart M, Harris L, Rimm DL, Tuck DP.

Cancer Inform. 2009;7:29-40. Epub 2008 Dec 23.

36.

Genomic analysis from tissue core biopsies: standard of care for the future?

Sarkar S, Tuck DP, Harris LN.

Breast Cancer Res Treat. 2009 Dec;118(3):645-6. doi: 10.1007/s10549-009-0337-x. Epub 2009 Feb 21. No abstract available.

PMID:
19234784
37.

Role for MKL1 in megakaryocytic maturation.

Cheng EC, Luo Q, Bruscia EM, Renda MJ, Troy JA, Massaro SA, Tuck D, Schulz V, Mane SM, Berliner N, Sun Y, Morris SW, Qiu C, Krause DS.

Blood. 2009 Mar 19;113(12):2826-34. doi: 10.1182/blood-2008-09-180596. Epub 2009 Jan 9.

38.

Long-term outcomes and clinicopathologic differences of African-American versus white patients treated with breast conservation therapy for early-stage breast cancer.

Moran MS, Yang Q, Harris LN, Jones B, Tuck DP, Haffty BG.

Cancer. 2008 Nov 1;113(9):2565-74. doi: 10.1002/cncr.23881.

39.

Macrophages directly contribute to the exaggerated inflammatory response in cystic fibrosis transmembrane conductance regulator-/- mice.

Bruscia EM, Zhang PX, Ferreira E, Caputo C, Emerson JW, Tuck D, Krause DS, Egan ME.

Am J Respir Cell Mol Biol. 2009 Mar;40(3):295-304. doi: 10.1165/rcmb.2008-0170OC. Epub 2008 Sep 5. Erratum in: Am J Respir Cell Mol Biol. 2012 Apr;46(4):561.

40.

Mutational load distribution analysis yields metrics reflecting genetic instability during pancreatic carcinogenesis.

Tarafa G, Tuck D, Ladner D, Topazian M, Brand R, Deters C, Moreno V, Capella G, Lynch H, Lizardi P, Costa J.

Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4306-11. doi: 10.1073/pnas.0708250105. Epub 2008 Mar 12.

41.

Association between pathways in regulatory networks.

Kluger Y, Kluger H, Tuck D.

Conf Proc IEEE Eng Med Biol Soc. 2006;1:2036-40.

PMID:
17946929
42.

Phase I and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system for paclitaxel.

Mita AC, Olszanski AJ, Walovitch RC, Perez RP, MacKay K, Tuck DP, Simmons C, Hammond S, Mita MM, Beeram M, Stone AJ, Rowinsky EK, Lewis LD.

Clin Cancer Res. 2007 Jun 1;13(11):3293-301.

43.
44.

MSVM-RFE: extensions of SVM-RFE for multiclass gene selection on DNA microarray data.

Zhou X, Tuck DP.

Bioinformatics. 2007 May 1;23(9):1106-14. Erratum in: Bioinformatics. 2007 Aug;23(15):2029.

PMID:
17494773
45.

A randomized controlled clinical trial to determine the optimum duration of G-CSF priming prior to BM stem cell harvesting.

Lowenthal RM, Ragg SJ, Anderson J, Nicholson L, Harrup RA, Tuck D.

Cytotherapy. 2007;9(2):158-64.

PMID:
17453967
46.

Differentiated cells are more efficient than adult stem cells for cloning by somatic cell nuclear transfer.

Sung LY, Gao S, Shen H, Yu H, Song Y, Smith SL, Chang CC, Inoue K, Kuo L, Lian J, Li A, Tian XC, Tuck DP, Weissman SM, Yang X, Cheng T.

Nat Genet. 2006 Nov;38(11):1323-8. Epub 2006 Oct 1.

PMID:
17013394
47.

A limited number of genes are involved in the differentiation of germinal center B cells.

Nakayama Y, Stabach P, Maher SE, Mahajan MC, Masiar P, Liao C, Zhang X, Ye ZJ, Tuck D, Bothwell AL, Newburger PE, Weissman SM.

J Cell Biochem. 2006 Dec 1;99(5):1308-25.

PMID:
16795035
48.

Cruella: developing a scalable tissue microarray data management system.

Cowan JD, Rimm DL, Tuck DP.

Arch Pathol Lab Med. 2006 Jun;130(6):817-22.

PMID:
16740033
49.
50.

Neuregulin-regulated gene expression in mammary carcinoma cells.

Amin DN, Tuck D, Stern DF.

Exp Cell Res. 2005 Sep 10;309(1):12-23.

PMID:
15963498

Supplemental Content

Support Center